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A selective and high-throughput liquid chromatographyemass spectrometry method has
been developed and validated for the simultaneous quantification of paroxetine, fampri-
dine, and quinidine in rat plasma using imipramine as an internal standard. Following
protein precipitation extraction, the analytes and internal standard were run on XBridge
C18 column (150 mm  4.6 mm, 5 mm) using a gradient mobile phase consisting of 5mM
ammonium formate in water (pH 9.0) and acetonitrile in a flow gradience program. The
precursor and product ions of the drugs were monitored on a triple quadrupole instrument
operated in the positive ionization mode. The method was validated over a concentration
range of 0.1e100 ng/mL for all the three analytes, with relative recoveries ranging from 69%
to 82%. The intra- and interbatch precision (percent coefficient of variation) across four
validation runs were less than 13.4%. The accuracy determined at four quality control (QC)
levels (lower limit of quantitation, low QC, medium QC, and high QC) was within ±6.5% of
coefficient of variation values. The method proved highly reproducible and sensitive, and
was successfully applied in a pharmacokinetic study after single-dose oral administration
to rats and also in perfusion study sample analysis.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Paroxetine (PRX) is a phenylpiperidine compound that acts as
a potent and selective serotonin reuptake inhibitor [1]. Itsaceutical Analysis, Hind
(S. Achanti).
inistration, Taiwan. Publis
/licenses/by-nc-nd/4.0/).action appears to account for the antidepressant activity
observed with this class of drugs [2] that are safe and effective
for the treatment of depressive and obsessiveecompulsive
disorders [3]. Fampridine (FMP; 4-aminopyridine) is a selectiveu College of Pharmacy, Amaravathi Road, Guntur 522 002, Andhra
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adult patientswithmultiple sclerosis to improve their walking
ability. Considering themechanism of action of FMP, there is a
plausible biological rationale to evaluate its usefulness in
symptomatic treatment ofmultiple sclerosis. Quinidine (QND)
is a Class I antiarrhythmic agent, which primarily works by
blocking the fast inward sodium current in the heart. Litera-
ture reveals that QND in combinationwith dextromethorphan
alleviates symptoms of easy laughing and crying (pseudo-
bulbar affect) in patients with amyotrophic lateral sclerosis
and multiple sclerosis [4]. Prescribing a single drug and its
administration are not sufficient in neurologic diseases such
as multiple sclerosis. Combination therapy, which can
decrease the number of medications for a single disease or its
associated diseases, is growing enormously. In clinical
research, estimation of concomitant drugs plays a key role in
the study of drugedrug interactions. Recently, Clinical Tri-
als.gov has updated information regarding Phase 4 studies of
FMP, along with concomitant drugs, in the treatment of mul-
tiple sclerosis disease. The research in the current article has
been undertaken to provide an accurate method that can be
applied to estimate FMP alongwith concomitant drugs such as
PRX and QND, which are prescribed as combination therapy.
In line with this, we have developed a method for the simul-
taneous estimation of PRX, QND, and FMP, which will be
highly useful in drugedrug interaction studies and also in
developing combined dosage forms. Even though indepen-
dent high-performance liquid chromatography and liquid
chromatographyemass spectrometry (LCeMS) methods are
available in the literature for the determination of PRX [5e8],
FMP [9,10], and QND [11e14], a technique for simultaneous
estimation of these three drugs neither is available nor has
been published. The aim of the current study is to develop and
validate a sensitive and high-throughput method for simul-
taneous determination of PRX, FMP, and QND in rat plasma for
therapeutic drug monitoring and pharmacokinetic studies
and also for in vivo perfusion studies in rats. The developed
bioanalytical method has been validated according to Inter-
national Conference on Harmonization (ICH) guidelines [15].
Structural formulas of the analytes are presented in Figure 1.2. Methods
2.1. Chemicals and reagents
PRX and QND were supplied by Sigma-Aldrich (Shanghai,
China). FMP was purchased from Sisco Research Laboratories
(Hyderabad, India). Acetonitrile of MS grade and other chem-
icals of analytical grade were obtained from Merck (Mumbai,
India). Water used in the study was prepared using the Milli-Q
water purification system (Millipore, Milford, MA, USA). Drug-
free rat plasma and rats were obtained from Albino research
Labs (Hyderabad, India) and the plasma was stored at 20C
until use.
2.2. Instrumentation
The liquid chromatography tandem-mass spectrometry
(LCeMS/MS)analysiswascarriedout inelectrospray ionizationpositive mode on a mass spectrometer (API 3000) coupled to a
Shimadzu LC system (model: SIL-HTC) operated with Analyst
1.6.1 software. Separation of all the analyteswas carried out on
an XBridge C18 column (150 mm length  4.6 mm internal
diameter, and 5 mmparticle size). Temperaturewas set at 30C.
The mobile phase composed of acetonitrile and 0.005M
ammonium formate pH 9.0 adjusted with ammonia (gradient
mode) in flow gradience of 0.5e2.0 mL/min in a run time of
4 minutes. The injection volume was 10 mL. The full-scan MS
and MS/MS spectra of each analyte were obtained by direct
infusion of the respective sample solution, at a concentration
of 10 mg/mL, prepared in methanol. The drugs were analyzed
using multiple reaction monitoring mode.2.3. Mass spectrometric conditions
Turbo ion spray interface operating in positive ionization
mode was used to study the parent / product ion (m/z)
transitions for PRX (330.1 / 192.1), FMP (94 / 67), QND
(325.1 / 251.1), and imipramine (281.4 / 86.1). Chemical
structures of all the four analytes are shown in Figure 1 and
the product ion spectra in Figure 2. Declustering potential,
entrance potential, collision energy, and collision exit poten-
tial were all optimized to allow the highest possible signal
transduction with low background noise. Signal optimization
was performed by constant infusion of 10 mg/mL drug solu-
tions in 100%methanol at a rate of 50 mL/min. The pressure of
the drying gas was 35 psi and the temperature was 350C. The
ion spray voltage was set at 4500 V and the pressure of colli-
sion gas (nitrogen) was 4 psi. Quadrupoles 1 and 3 were set at
unit mass resolution, and each multiple reaction monitoring
transition was monitored with a dwell time of
200 milliseconds.2.4. Standard solutions and fortification
Standard stock solutions of PRX, FMP, and QNDwere prepared
by accurately weighing 10 mg of each standard on a closed
electronic microbalance (Sartorius, Goettingen, Germany) and
dissolving them separately in 10 mL of methanol. Individual
working solutions of analytes were prepared by appropriate
dilution of their stock solutions in 50% methanol. All the so-
lutions were stored in a refrigerator at or below 10C and were
brought to room temperature before use. A working solution
of then internal standard (ISTD; imipramine 500 ng/mL) was
prepared daily in 50% methanol and stored at room temper-
ature. Calibration standards and quality control (QC) samples
were prepared by spiking (3%) blank plasma with the working
solutions prepared from independent stock weightings. Cali-
bration standards for PRX, FMP, and QND were prepared at
concentrations of 0.1 ng/mL, 0.2 ng/mL, 0.5 ng/mL, 1 ng/mL,
5 ng/mL, 10 ng/mL, 50 ng/mL, and 100 ng/mL. QC samples
were prepared at 0.1 ng/mL [lower limit of quantitation (LLOQ)
QC], 0.3 ng/mL [low QC (LQC)], 40 ng/mL [medium QC (MQC)],
and 80 ng/mL [high QC (HQC)] for all the three analytes. Ali-
quots (0.3 mL) of spiked plasma samples were taken in poly-
propylene tubes and stored at 70C. Prior to analysis, all
frozen subject samples, calibration standards, and QC sam-
ples were thawed unassisted at room temperature and
Figure 1 e Chemical structures of four analytes.
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the next section.
2.5. Sample preparation
A simple protein precipitationmethodwas used to extract the
analytes. Plasma samples stored at around 70C were
thawed, left for 1 hour, and vortexed for 30 seconds at room
temperature before extraction to ensure homogeneity.
Acetonitrile (150 mL) was added as a protein precipitating
agent, vortexed for 1 minute, and then centrifuged at
10,000 rpm for 10 minutes on refrigerated centrifuge at 4C.
The supernatant layer was separated and filtered through
0.45 mm syringe filters, and 10 mL of the solution was injected
for LCeMS/MS analysis. Perfusion samples were collected at
certain time points, centrifuged at 5000 rpm for 10 minutes,
and analyzed.
2.6. Method validation
A complete method validation of PRX, FMP, and QND in rat
plasma was done following the United States Food and Drug
Administration and European Medicines Agency (EMEA)
guidelines. Validation runs were performed on 7 separate days
to evaluate selectivity, sensitivity, linearity, precision, accuracy,
recovery, matrix effect, dilution integrity, and stability of the
method. Each validation runwas organizedwith a set of spiked
standard samples, blank (with ISTD and without ISTD), and QC
samples as per the validation parameters. Standard samples
wereanalyzedat thebeginningof the run, andQCsampleswere
distributed consistently throughout the validation runs.Selectivity of the method toward endogenous and exogenous
components of plasmawas evaluated in 12different rat plasma
lots. The blank plasma lots were extracted (without addition of
ISTD) and injected for LCeMS/MS detection. Later, selectivity in
each lot was evaluated by comparing the blank peak responses
with the mean peak response observed in plasma spiked LLOQ
sample (n ¼ 6). The potential for assay interference from
concomitant drugs was also investigated by spiking LQC sam-
ples with teriflunomide, ibuprofen, tamsulosin, and pioglita-
zone. Linearity of the method was assessed using four
calibration curves analyzed on 3 different days. Each plot was
associated with eight-point nonzero concentrations spread
over the dynamic range. A linear least squares regression
analysiswith the reciprocal ofdrugconcentration asaweighing
factor (1/X2) was performed on peak area ratios versus analyte
concentrations. Peak area ratios for plasma spiked calibration
standards were proportional to the concentrations of analytes
over the established range.
Intrabatch (within day) and interbatch (between day) pre-
cision and accuracy were evaluated at four distinct concen-
trations (LLOQ, LQC, MQC, and HQC) for each analyte.
Precision and accuracy at each concentration level were
evaluated in terms of percent coefficient of variation (%CV)
and relative error, respectively. The extraction recovery of
PRX, FMP, and QND was determined at LQC, MQC, and HQC
levels. Relative recoveries were evaluated by comparing the
peak areas of extracted samples (spiked before extraction)
with those of unextracted samples (blank extracts spiked after
extraction). The matrix effect was checked at LQC and HQC
levels using six different blank plasma lots (including 1 he-
molytic and 1 lipemic lot). Matrix factors for analyte and ISTD
Figure 2 e Product ion spectra of (A) quinidine, (B) paroxetine, (C) fampridine, and (D) imipramine.
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of postextraction samples (blank extracts spiked after
extraction) with the peak responses of equivalent aqueous
samples prepared in the mobile phase. ISTD normalizedmatrix factor in each lot was later evaluated by comparing the
matrix factors of analyte and ISTD. Stability of analytes in
both aqueous solutions and biological matrix was evaluated
after subjecting them to different conditions and
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ysis. Stability in plasma was evaluated in terms of freeze-
ethaw stability, bench-top stability, long-term stability, and
extracted sample stability. Freezeethaw stability was evalu-
ated after four freeze (at 70C)ethaw (at room temperature)
cycles. Bench-top stability was assessed at room temperature,
and long-term stability was evaluated at both 70C and
20C. Stability of extracted samples was determined as
autosampler stability at 10C. Stability in plasma was evalu-
ated at room temperature. All the stability assessments were
made at LQC and HQC levels by comparing the stability sam-
ples with freshly prepared samples. Stability of analytes in
stock solutions and working solutions was assessed at room
temperature (short-term stability) and at 1e10C (long-term
stability). All comparisons were made against freshly pre-
pared stock solutions or working solutions. The method was
cross-validated for determination of PRX and FMP only (in
absence of QND) and for determination of QND only (in
absence of PRX and FMP). In cross-validation, two indepen-
dent precision and accuracy runs, one for the determination
of PRX and FMP and the other for the determination of QND
only, were evaluatedwith LQC,MQC, andHQC samples (n¼ 6).
During routine analysis, each analytical run was organized
with a set of standard samples, a set of QC samples in dupli-
cate, and plasma samples to be determined. Prior to each
analytical run, system suitability was evaluated by injecting
six replicates of upper limit of quantitation sample and three
replicates of LLOQ sample, to check the system precision and
accuracy. System suitability was considered acceptable when
the CV for response ratios was less than 4.0%.Table 1 e Gradient program.
Time (min) Buffer (%) Acetonitrile (%) Flow rate (mL/min)
Initial 95 5 1.0
1.0 95 5 1.0
1.2 5 95 2.0
3.0 5 95 2.0
3.2 95 5 1.0
4.0 95 5 1.03. Results
3.1. Method development
For consistent and reliable estimation of analytes, it was
necessary to give equal importance to optimization of
extraction procedure, and chromatographic and mass spec-
trometric conditions. Analytes and ISTD were tuned in both
positive and negative polarity modes using electrospray ioni-
zation technique; however, positive ion mode showed better
selectivity and sensitivity for PRX. The Q1 and MSeMS scans
were made in infusion mode, and further compound and gas
parameters were optimized in flow injection analysis. The
[M þ H]þ peaks were observed atm/z values of 330.4, 94.0, and
325.1, for PRX, FMP, and QND, respectively. Most abundant
product ions were found at an m/z of 192.1 for PRX, 67.0 for
FMP, and 251.1 for QND, by applying sufficient collision-
activated dissociation gas and collision energy. An increase
in source temperature beyond 350C augmented the intensity
for all analytes except FMP. A 5% change in ion spray voltage
and gas parameters did not affect the signal intensity. In the
optimization of chromatographic conditions, the isocratic
mode was selected as no crosstalk was observed between
analytes and ISTD. To facilitate protonation pH adjusted to 9.0
with ammonia to the ammonium formate buffer. Use of
methanol over acetonitrile in the mobile phase has shown
significant improvement in signal intensities. Replacement of
Milli-Q water with 5mM ammonium formate buffer in themobile phase resulted in good chromatographic peak shapes,
and a further increase in the buffer concentration resulted in a
loss of FMP response. A flow gradience of 0.5e1.5 mL/min was
used to minimize the run time without compromising the
signal intensity (Table 1). Multiple reaction monitoring chro-
matograms are presented in Figure 3.
3.2. Selectivity
Selectivity of themethod in rat K2EDTA plasmawas evaluated
in 12 individual matrix lots, including one lipemic and one
hemolytic lot. Peak responses in blank lots were compared
with the response of the spiked LLOQ, and negligible inter-
ference was observed at the retention time of analytes and
ISTD.
3.3. Linearity and sensitivity
The linearity of each calibration curve was determined by
plotting the peak area ratio (y-axis) of analytes to ISTD versus
the nominal concentration (x-axis) of analytes. Calibration
curves were linear from 0.1 ng/mL to 100 ng/mL for PRX, FMP,
and QND, with r2 values beingmore than 0.9962. The r2 values,
slopes, and intercepts were calculated from four intra- and
interday calibration curves using weighted (1/X2) linear
regression analysis. The observed mean back-calculated
concentrations with accuracy (percent relative error) and
precision (%CV) are presented in Table 2. The LLOQwas found
to be 0.1 ng/mL for all the three analytes, and accuracy was in
the range of 69e82%, with a %CV of 6.5%. At LLOQ, the mean
signal-to-noise ratios were found to be 26:1, 39:1, and 170:1 for
PRX, FMP, and QND, respectively.
3.4. Precision and accuracy
Precision and accuracy were evaluated using four intra- and
interday precision and accuracy runs, with each batch con-
sisting of six replicates of QC samples at four concentration
levels (LLOQ, LQC, MQC, and HQC). The intra- and interbatch
precision were less than 13.4% for FMP, PRX, and QND, with
accuracy (percent relative error) between 0.1 and 11.7. Results
of precision and accuracy are presented in Table 3.
3.5. Matrix effect
Coeluting matrix components can suppress or enhance ioni-
zation, but may not result in a detectable response in matrix
blanks due to selectivity of MS detection; however, they can
affect the precision and accuracy of the assay. Therefore, the
Figure 3 e Extracted ion chromatograms of (A) blank plasma, (B) blank plasma spiked with analytes and Internal Standard
(IS), and (C) plasma sample after a single oral dose of three analytes QND, PRX, and FMP. FMP ¼ fampridine;
IMP ¼ imipramine; PRX ¼ paroxetine; QND ¼ quinidine.
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Table 2 e Summary of calibration standards.
Analyte Nominal
concentration
(ng/mL)
Actual
concentration
(ng/mL) (n ¼ 4)
%CV %RE
PRX 0.101 0.103 8.7 2.0
0.203 0.198 13.8 2.5
0.507 0.506 11.1 0.2
1.015 0.943 5.6 7.1
5.074 4.986 5.0 1.7
10.147 9.944 3.2 2.0
50.737 53.289 2.8 5.0
101.474 107.730 6.6 6.2
FMP 0.101 0.102 4.3 1.0
0.202 0.198 7.2 2.0
0.505 0.507 7.0 0.4
1.010 1.003 2.9 0.7
5.051 4.962 5.0 1.8
10.101 9.921 2.6 1.8
50.505 51.201 3.0 1.4
101.011 102.401 7.4 1.4
QND 0.101 0.103 4.3 2.0
0.202 0.199 3.8 1.5
0.504 0.505 1.3 0.2
1.000 1.003 1.1 0.3
5.040 4.990 2.7 1.0
10.090 9.979 1.2 1.1
50.400 50.455 2.9 0.1
100.900 100.676 4.5 0.2
%CV ¼ percent coefficient of variation; FMP ¼ fampridine;
PRX ¼ paroxetine; QND ¼ quinidine; %RE ¼ percent relative error.
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 4 ( 2 0 1 6 ) 8 6 6e8 7 5872potential for variable matrix-related ion suppression was
evaluated in six independent sources (containing 1 hemolytic
and 1 lipemic lot) of rat plasma, by calculating the Internal
Standard (IS) normalized matrix factor. The mean IS normal-
izedmatrix factor for all the three analytes ranged between 0.9
and 1.1 with a %CV of 10.7, as shown in Table 4.Table 3 e Intra- and interbatch precision and accuracy.
Analyte Nominal concentration (ng/mL) In
% Recovery
Paroxetine
LLOQQC 0.101 104.12
LQC 0.301 101.65
MQC 40.118 106.02
HQC 80.236 100.67
Fampridine
LLOQQC 0.101 108.18
LQC 0.302 105.23
MQC 40.221 100.13
HQC 80.443 96.41
Quinidine
LLOQQC 0.101 105.26
LQC 0.302 97.39
MQC 40.221 107.05
HQC 80.443 99.80
%CV ¼ percent coefficient of variation; HQC ¼ high quality control; LQC ¼
relative error.3.6. Extraction recovery and dilution integrity
The extraction recovery of analytes from EDTA plasma was
determined by comparing the peak responses of plasma
samples (n ¼ 6) spiked before extraction with those of plasma
samples spiked after extraction. The mean recovery rates of
PRX, FMP, and QND were found to be 74.9%, 78.7%, and 76.6%,
respectively, with %CV across the three levels ranging be-
tween 4.7% and 7.7%, as shown in Table 5. Dilution integrity
experiment was carried out at two times the upper limit of
quantification concentration for all the three analytes. After 1/
2 and 1/4 dilution, themean back-calculated concentration for
dilution QC samples was within 85e115% of nominal value,
with a %CV of 9.0. Similarly, LQC samples spiked with
concomitant drugs were quantified within 15% of nominal
value with a %CV of 6.5.
3.7. Stability
Stability evaluations were performed in both aqueous and
matrix-based samples. The stock solutions were stable for a
period of 24 hours at room temperature and for 60 days at
1e10C. Stability evaluations in matrix were performed
against freshly spiked calibration standards using freshly
prepared QC samples (comparison samples). PRX, FMP, and
QND were stable up to 10 hours on bench top at room tem-
perature and over five freezeethaw cycles. The processed
sampleswere stable up to 36 hours in the autosampler at 10C.
Long-term matrix stability was evaluated at both 20C and
70C over a period of 60 days. No significant degradation of
analytes was observed over the stability duration and condi-
tions. The stability results presented in Table 6 were within
85e115%. Stability in rat plasma was evaluated at both LQC
and HQC levels by comparing the mean response ratios of
stability samples with those of the comparison samples. The
stability of analytes at room temperature was within 85e115%
for up to 24 hours.traday (n ¼ 6) Interday (n ¼ 24)
%CV %RE % Recovery %CV %RE
13.4 1.4 105.01 7.1 3.0
12.3 1.7 101.97 3.3 1.9
4.1 6.0 107.72 3.0 7.7
6.0 0.7 101.55 2.1 1.6
8.8 8.2 111.68 5.6 11.7
8.0 5.2 104.23 1.9 4.2
4.1 0.1 103.90 6.3 3.9
4.7 3.6 97.40 2.2 2.6
5.1 5.3 102.87 4.78 2.6
5.4 2.6 98.99 4.33 1.7
4.3 7.1 108.52 0.56 6.8
3.5 0.2 99.65 0.89 0.3
low quality control; MQC ¼medium quality control; %RE ¼ percent
Table 4 e Matrix effect results.
Analyte Paroxetine Fampridine Quinidine
LQC HQC LQC HQC LQC HQC
MF ISNMF MF ISNMF MF ISNMF MF ISNMF MF ISNMF MF ISNMF
Lot 1 1.0602 0.9153 1.1295 1.0119 1.0526 0.9130 1.0708 0.9589 0.9880 0.9333 0.9885 0.9700
Lot 2 1.0381 0.9153 1.0824 0.9783 1.0745 0.9783 1.0170 0.9189 0.9841 1.0000 0.9944 0.9514
Lot 3 1.1619 1.1186 1.1007 0.9257 1.0442 0.9783 1.0985 0.9236 1.0388 1.0000 1.0171 0.9281
Lot 4 1.0471 0.9153 1.1467 0.9856 1.0698 0.9130 1.0478 0.9003 0.9128 0.9333 1.0147 0.9121
Lot 5 1.0855 0.9153 1.1117 0.9949 1.0142 0.8478 1.0916 0.9764 1.0734 0.8667 1.0115 0.9407
Lot 6 1.2419 1.1186 1.1421 1.0187 1.0331 0.9130 1.0474 0.9340 0.8948 0.9333 1.0295 0.9579
Mean 0.9831 0.9858 0.9239 0.9354 0.9444 0.9433
%CV 10.7 3.4 5.3 3.0 5.3 2.2
%CV ¼ percent coefficient of variation; HQC ¼ high quality control; ISNMF ¼ internal standard normalized matrix factor; LQC ¼ low quality
control; MF ¼ matrix factor.
Table 5 e Extraction recovery for PRX, FMP, and QND (n ¼ 6).
Analyte QC level A B % Recovery Mean % recovery %CV
Paroxetine LQC 2099.5 1647.2 78.5 74.9 6.5
MQC 249,300.8 191,633.2 76.9
HQC 512,079.2 354,884.0 69.3
Fampridine LQC 3114.5 2556.0 82.1 78.7 4.7
MQC 431,623.2 342,272.7 79.3
HQC 876,272.5 655,047.5 74.8
Quinidine LQC 2285.3 1607.5 70.3 76.6 7.7
MQC 428,802.5 331,623.2 77.3
HQC 792,491.2 649,851.5 82.0
A ¼ mean response in extraction samples; B ¼ mean response in postextraction spiked samples; %CV ¼ percent coefficient of variation;
FMP ¼ fampridine; HQC ¼ high quality control; LQC ¼ low quality control; MQC ¼ medium quality control; PRX ¼ paroxetine; QC ¼ quality
control; QND ¼ quinidine.
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In order to verify the sensitivity and selectivity of the devel-
oped method in a real-time situation, the developed LCeMS/
MS method was successfully applied to a pharmacokinetic
study by administration of PRX, FMP, and QND as a single
solution to six male Wistar rats by oral route, using a BD sy-
ringe attached with an oral gavage needle (size 18) at the dose
of 3 mg/kg body weight. Approximately 0.2 mL of blood sam-
ple from each anesthetized (isoflurane) rat, at predetermined
time intervals, was collected using a capillary tube into
prelabeled Eppendorf tubes containing 10% of K2EDTA anti-
coagulant (20 mL). The time intervals for the sample collection
were 0 hours (predose), 0.5 hours, 1 hour, 2 hours, 4 hours,
6 hours, 8 hours, 12 hours, and 24 hours (postdose). The total
blood volume collected from each rat was approximately
1.7e1.9 mL, which does not exceed the maximal recom-
mended blood volume of 20% (2.0 mL for a rat with 200 g body
weight). Plasma was obtained by centrifuging blood samples
at 4000 rpm for 10 minutes. The obtained plasma samples
were transferred into prelabeled microcentrifuge tubes and
stored at 50C. All the samples were analyzed by the devel-
oped method, and the mean plasma concentrations versus
time profiles of PRX, FMP, and QND are shown in Figure 4. A
noncompartmental model was used to estimate the phar-
macokinetic parameters in rat plasma. After oraladministration of the three drugs, peak plasma concentra-
tions (Cmax) were reached at the time to reach maximum
concentration (Tmax) of 2.00 hours, 6.00 hours, and 2.00 hours
with an elimination half-life (t1/2) of 5.912 ± 0.431 hours,
12.012 ± 2.115 hours, and 6.401 ± 0.885 hours for FMP, PRX, and
QND respectively by LCeMS.3.9. Application of the method to perfusion study
Ratswereanesthetizedwithan intramuscular injectionof1mL/
kg of ketamineexylazine solution (9:1), placed on a heated
surface maintained at 37C (Harvard Apparatus Inc., Holliston,
MA, USA), and a 3 cmmidline abdominal incision wasmade. A
proximal 10 cm jejuna segment, starting 2 cm below the liga-
ment of Treitz, was cannulated on two ends and rinsed with
blank perfusion buffer. All solutions were incubated in a 37C
water bath. At the starting point of each experiment, the
perfusion solution containing the investigated drug, 10mM
perfusion buffer (pH 6.5), 135mM NaCl, 5mM KCl, and 0.01 mg/
mL phenol red, with an osmolarity of 290 mOsm/L, was
perfused through the intestinal segment ata flowrateof 0.2mL/
min. The perfusion buffer was perfused for 1 hour without
sampling, to ensure steady-state conditions, followed by addi-
tional 1 hour of perfusionwith samples taken every 10minutes.
The pH of the collected samples wasmeasured at the outlet, to
verify that there was no pH change throughout the perfusion
Table 6 e Stability studies of PRX, FMP, and QND in rat plasma at LQC and HQC levels (n ¼ 6).
Stability Analyte QC level A %CV B %CV % Stability
Bench-top stability (12 h at ~25C) PRX LQC 0.29 5.8 0.32 13.3 90.6
HQC 83.75 2.3 80.66 4.1 103.8
FMP LQC 0.29 10.6 0.30 9.0 96.7
HQC 84.66 1.7 80.17 2.9 105.6
QND LQC 0.31 14.7 0.28 12.5 110.7
HQC 87.9 11.3 87.80 10.0 100.1
Freezeethaw stability (after 5th cycle) PRX LQC 0.33 12.6 0.32 7.6 103.1
HQC 79.75 4.3 82.66 4.3 96.5
FMP LQC 0.30 5.7 0.31 5.7 96.8
HQC 79.37 5.2 79.26 2.8 100.1
QND LQC 0.30 5.6 0.31 0.51 96.8
HQC 83.30 4.6 79.75 9.8 104.5
In-injector stability (at 10C for 36 h) PRX LQC 0.33 8.1 0.32 13.1 103.1
HQC 81.18 4.5 83.39 5.4 97.3
FMP LQC 0.30 8.3 0.31 4.1 96.8
HQC 82.67 4.4 79.89 4.8 103.5
QND LQC 0.30 10.0 0.30 8.9 100.0
HQC 77.27 3.3 79.57 2.1 97.1
Long-term stability (at 20C for 60 d) PRX LQC 0.30 4.2 0.32 13.3 93.8
HQC 78.10 6.6 80.66 4.1 96.8
FMP LQC 0.29 7.1 0.30 9.0 96.7
HQC 73.70 9.1 80.17 2.9 91.9
QND LQC 0.31 4.0 0.28 12.5 110.7
HQC 77.50 3.4 87.80 10.0 88.3
Long-term stability (at 70C for 60 d) PRX LQC 0.31 0.6 0.32 13.3 96.9
HQC 77.99 6.6 80.66 4.1 96.7
FMP LQC 0.28 4.7 0.30 9.0 93.3
HQC 74.30 7.4 80.17 2.9 92.7
QND LQC 0.32 3.6 0.28 12.5 114.3
HQC 77.88 8.9 87.80 10.0 88.7
A ¼ mean concentration (ng/mL) of stability samples; B ¼ mean concentration (ng/mL) of comparison samples; %CV ¼ percent coefficient of
variation; FMP ¼ fampridine; HQC ¼ high quality control; LQC ¼ low quality control; MQC ¼ medium quality control; PRX ¼ paroxetine;
QC ¼ quality control; QND ¼ quinidine.
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 4 ( 2 0 1 6 ) 8 6 6e8 7 5874procedure (pH 6.5). The samples were immediately assayed by
LCeMS. The length of the perfused intestinal segment was
measured at the end point of the experiment. The effective
permeability (Peff, cm/s) through the rat gut wall was deter-
mined according to the following equation:Figure 4 e Mean plasmaetime concentration profiles of
QND, PRX, and FMP. Concn e concentration;
FMP ¼ fampridine; IMP ¼ imipramine; PRX ¼ paroxetine;
QND ¼ quinidine.Peff ¼ eQ lnðCout=CinÞ2pRL
where Q is the perfusion buffer flow rate (0.2 mL/min), Cout/Cin
is the ratio of the outlet concentration to the inlet concen-
tration of drug that has been adjusted for water transport via
the nonabsorbable marker phenol red, R is the radius of the
intestinal segment (set to 0.2 cm), and L is the length of the
perfused intestinal segment. All the sampleswere analyzed by
LCeMS in the proposed method, and the results are shown in
Figure 5.4. Discussion
A rapid, sensitive, and accurate LC with electrospray ioniza-
tion tandem mass spectrometry method was developed for
simultaneous determination of PRX, FMP, and QND in rat
plasma, with a chromatographic run time of 4 minutes. This
method offers high selectivity and equal sensitivity to other
methods, with a limit of quantitation of 0.1 ng/mL for all the
three analytes. The extraction method utilizes a low sample
volume of 50 mL, and has shown consistent and reproducible
recoveries for analytes and ISTD with minimum plasma
interference and matrix effect. The developed method was
successfully applied to a pharmacokinetic study using the test
formulation at 3 mg/kg and also for an in vivo perfusion study
Figure 5 e Perfusion study results. FMP ¼ fampridine;
IMP ¼ imipramine; PRX ¼ paroxetine; QND ¼ quinidine.
j o u r n a l o f f o o d and d ru g an a l y s i s 2 4 ( 2 0 1 6 ) 8 6 6e8 7 5 875at 1 mg/mL dose. The concomitant drug analysis along with
the target analyte is more advantageous than single com-
pound analysis, and is also useful in drug interaction and
toxicology studies. This validated method can be used for the
analysis of patient samples receiving PRX, FMP, and QND, to
support clinical pharmacokinetic studies.Conflicts of interest
None.
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